Velpharm

History

2023: Launch of production of drugs in the SEZ "Technopolice Moscow" for 2.5 billion rubles

At the end of January 2023, Velpharm launched a drug production plant on the territory of the Technopolice Moscow SEZ. About 2.5 billion rubles were invested in the implementation of the project.

The company will produce more than 80 names of vital drugs included in the list: from diseases of the cardiovascular system, from liver diseases, to reduce blood cholesterol. The production of "a large number for other therapeutic groups" will also be established, said Ilya Titov, technical director of Velfarm.

Plant of the company "Velpharm" in the SEZ "Technopolice Moscow"

According to him, by the end of January 2023, small-scale production was launched, which is developing technologies. A chemical and analytical laboratory has also been launched, where the results of this production are analyzed. It is planned to launch larger lines and workshops starting from the first quarter of 2023. The company also added that after reaching full capacity, almost 1,500 people will be able to work at the plant.

The head of the Federation Council Valentina Matvienko took part in the opening of the complex, according to her, the launch of the complex is a significant event for the entire domestic pharmaceutical industry.

This work is very important not only for the technological, medical sovereignty of the country, but, above all, for the preservation of the health and life of our citizens. We can and must be the best, "she said.

The construction of the plant is carried out with state support. Thus, 1.5 billion rubles in the form of preferential loans to the enterprise were provided by the Federal Industrial Development Fund (FRP). The Moscow Fund for Industry and Entrepreneurship Support compensates for part of the cost of paying interest on loan agreements totaling more than 1.6 billion rubles. The company invested a total of 4 billion rubles in the creation of production.^[1]

2015: Construction of a plant in Kurgan

Velpharm is building a medical plant in Kurgan, where it plans to annually produce up to 4.5 million packages of injection solutions, up to 20 million tubes of ointments and gels, up to 32.5 million packages of coated tablets and capsules, up to 15 million packages of crumbles. The total portfolio of products planned for production includes more than 60 drugs (37 of which are import-substituting).

Among the drugs that are currently undergoing testing and registration stages: five antibiotics, three nonsteroidal anti-inflammatory drugs, two hypoglycemic drugs (for the treatment of diabetes mellitus), two lipid-lowering drugs (for lowering cholesterol concentration), agents for the treatment of acne, peptic ulcer disease, epilepsy, antiallergic and antiparkinsonic drugs and other drugs.

Of the planned assortment of finished dosage forms, more than 55% are represented on the Russian market only by foreign manufacturers and have not yet been produced in the Russian Federation, 43% are very poorly localized and domestic products from this list provide only 1-6% of the existing drug market.

The drugs produced at the plant are supposed to be sold not only in, Russia but also in Azerbaijan, Armenia Afghanistan,,, Vietnam, Belarus Kazakhstan Georgia Kyrgyzstan, Moldova, Mongolia, Tajikistan,. Uzbekistan

The project cost is 1.1 billion, rubles while the loan of the Industrial Development Fund may amount to 500 million rubles. It is planned to create 334 high-tech jobs.

Notes